Determination of free and total meropenem levels in human plasma and its application for the consistency evaluation of generic drugs
Rapid Communications in Mass Spectrometry · 2023
DOI: 10.1002/rcm.9460 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rapid Communications in Mass Spectrometry, 2023. Verfasst von Ping Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Drugs, Generic, Tandem Mass Spectrometry. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Major Research Projects of the Ministry of Science and Technology of China, the Key Clinical Project of Peking University Third Hospital.
Abstract (Originalsprache)
Rationale
The consistency evaluation of generic drugs is important for the overall reformation of drug registration in China. In this study, we used meropenem as a model drug to explore the key techniques for clinical consistency evaluation by studying the plasma protein binding (PPB) ratio of different preparations. Because the free portion of drug is the effective part in vivo , it is essential to measure the free drug concentration in the circulatory system. Therefore, in this study, a fast and accurate high‐performance liquid chromatography tandem mass spectrometry (HPLC–MS/MS) method was developed to determine the total and free concentrations of meropenem in human plasma.
Methods
Simple protein precipitation procedures were used for the sample processing assay, and ultrafiltration was implemented for the separation of free drugs. Liquid chromatography separation was performed using a hydrophilic interaction liquid chromatography (HILIC) silica column (2.1 × 50 mm, 3 μm). The mobile phase and sample preparation procedures were optimized. Factors affecting the measurement of free drug concentration were also determined. Nonspecific binding of the ultrafiltration membrane was negligible because the recovery rate for post‐ultrafiltration was greater than 96%.
Results
Under optimal conditions, the drug concentrations were linear from 0.5 to 50 μg/ml for both total and free drug concentrations. The PPB ratio was calculated based on the free and total drug concentrations. The PPB of meropenem varied from 1.4% to 24.2% in different subjects. The validated method was applied to evaluate PPB of four preparations, and the results varied from 6.57 ± 3.19% to 10.40 ± 8.31%. One‐way analysis of variance (ANOVA) showed no significant differences between the four preparations.
Conclusions
We established a rapid, robust, and reliable method for the determination of total and free meropenem concentrations using LC–MS/MS with ultrafiltration techniques. The method provided a new perspective for the clinical consistency evaluation of generic drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Peking University Third Hospital, Beijing, China.
- Therapeutic Drug Monitoring and Clinical Toxicology Center of Peking University, Beijing, China.
- National Institute for Food and Drug Control, Beijing, China.
ORCID-Profile: Xianhua Zhang
Förderung
- Major Research Projects of the Ministry of Science and Technology of China
- the Key Clinical Project of Peking University Third Hospital
Zitieren
APA
Yang, P., Zhang, X., Zhou, C., Zhai, S., Wang, C., & Yang, L. (2023). Determination of free and total meropenem levels in human plasma and its application for the consistency evaluation of generic drugs. Rapid Communications in Mass Spectrometry. https://doi.org/10.1002/rcm.9460
Vancouver
Yang P, Zhang X, Zhou C, Zhai S, Wang C, Yang L. Determination of free and total meropenem levels in human plasma and its application for the consistency evaluation of generic drugs. Rapid Communications in Mass Spectrometry. 2023. doi:10.1002/rcm.9460
BibTeX
@article{Yang2023,
author = {Yang, Ping and Zhang, Xianhua and Zhou, Congya and Zhai, Suodi and Wang, Chen and Yang, Li},
title = {Determination of free and total meropenem levels in human plasma and its application for the consistency evaluation of generic drugs},
journal = {Rapid Communications in Mass Spectrometry},
year = {2023},
doi = {10.1002/rcm.9460}
}
EUVIMED